Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity

References

• Meites E, Kempe A, Markowitz LE. Use of a 2-Dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016;65:1405–08. doi:10.15585/mmwr.mm6549a5.
   PubMed Web of Science ®Google Scholar
• Dempsey AF, Schaffer SE, Cohn LM. Follow-up analysis of adolescents partially vaccinated against human papillomavirus. J Adolesc Health. 2012;50:421–23. doi:10.1016/j.jadohealth.2011.08.017.
   PubMed Web of Science ®Google Scholar
• Tan W, Viera AJ, Rowe-West B, Grimshaw A, Quinn B, Walter EB. The HPV vaccine: are dosing recommendations being followed? Vaccine. 2011;29:2548–54. doi:10.1016/j.vaccine.2011.01.066.
   PubMed Web of Science ®Google Scholar
• Widdice LE, Bernstein DI, Leonard AC, Marsolo KA, Kahn JA. Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics. 2011;127:77–84. doi:10.1542/peds.2010-0812.
   PubMed Web of Science ®Google Scholar
• Esposito S, Birlutiu V, Jarcuska P, Perino A, Man SC, Vladareanu R, Meric D, Dobbelaere K, Thomas F, Descamps D, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study. Pediatr Infect Dis J. 2011;30:e49–55. doi:10.1097/INF.0b013e318206c26e.
   PubMed Web of Science ®Google Scholar
• Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis. 2013;208:1325–34. doi:10.1093/infdis/jit363.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Zimmerman RK, Nowalk MP, Huang HH, Raviotta JM. Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males. Vaccine. 2014;32:693–99. doi:10.1016/j.vaccine.2013.11.098.
   PubMed Web of Science ®Google Scholar
• Widdice LE, Unger ER, Panicker G, Hoagland R, Callahan ST, Jackson LA, Berry AA, Kotloff K, Frey SE, Harrison CJ, et al. Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals. Vaccine. 2018;36:881–89. doi:10.1016/j.vaccine.2017.12.042.
   PubMed Web of Science ®Google Scholar
• Zimmerman RK, Nowalk MP, Lin CJ, Fox DE, Ko FS, Wettick E, Cost G, Hand L, Hayes J, Michaels M, et al. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J Womens Health (Larchmt). 2010;19:1441–47. doi:10.1089/jwh.2009.1753.
   PubMed Web of Science ®Google Scholar
• Russell K, Dunne EF, Kemper AR, Dolor RJ, Unger ER, Panicker G, Markowitz LE, Walter EB. Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals. Vaccine. 2015;33:1953–58. doi:10.1016/j.vaccine.2015.02.058
   PubMed Web of Science ®Google Scholar
• Herrero R, Gonzalez P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015;16:e206–16. doi:10.1016/S1470-2045(14)70481-4.
   PubMed Web of Science ®Google Scholar
• Schiller JT, Muller M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol. 2015;16:e217–25. doi:10.1016/S1470-2045(14)71179-9.
   PubMed Web of Science ®Google Scholar
• Scherpenisse M, Schepp RM, Mollers M, Meijer CJ, Berbers GA, van der Klis FR. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One. 2013;8:e74797.
   PubMed Web of Science ®Google Scholar
• Schurink-van ‘t Klooster TM, Donken R, Schepp RM, van der Klis FRM, de Melker HE. Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule. Vaccine. 2018;36:7580–87. doi:10.1016/j.vaccine.2018.10.018.
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis. 1998;177:1112–15. doi:10.1086/jid.1998.177.issue-4.
   PubMed Web of Science ®Google Scholar
• Boxus M, Lockman L, Fochesato M, Lorin C, Thomas F, Giannini SL. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine. 2014;32:3232–36. doi:10.1016/j.vaccine.2014.04.005.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, Nene BM, Esmy PO, Joshi S, Poli URR, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17:67–77. doi:10.1016/S1470-2045(15)00414-3.
   PubMed Web of Science ®Google Scholar
• Brady AM, Unger ER, Panicker G. Description of a novel multiplex avidity assay for evaluating HPV antibodies. J Immunol Methods. 2017;447:31–36. doi:10.1016/j.jim.2017.04.004.
   PubMed Web of Science ®Google Scholar
• Panicker G, Rajbhandari I, Gurbaxani BM, Querec TD, Unger ER. Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types. J Immunol Methods. 2015;417:107–14. doi:10.1016/j.jim.2014.12.013.
   PubMed Web of Science ®Google Scholar
• Petras M, Sykora T, Andrys C, Drahosova M. Post-vaccination anti-human papillomavirus antibody seroprevalence among Czech teenaged girls and women. Int J Gynaecol Obstet. 2012;119:178–81. doi:10.1016/j.ijgo.2012.06.007.
   PubMed Web of Science ®Google Scholar